Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature

This publication has 31 references indexed in Scilit:

• Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era
  Hematological Oncology, 2022
• Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma
  Transplantation and Cellular Therapy, 2021
• Molecular biology of Hodgkin lymphoma
  Leukemia, 2021
• Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement
  Hematological Oncology, 2020
• Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
  JAMA Oncology, 2020
• Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
  European Journal of Cancer, 2019
• CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
  Hematological Oncology, 2017
• Isolated central nervous system relapses in primary mediastinal large B‐cell lymphoma after CHOP‐like chemotherapy with or without Rituximab
  Hematological Oncology, 2012
• Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes
  Journal of the Neurological Sciences, 2006
• CSF analysis of IgH gene rearrangement in CNS lymphoma: Relationship to the disease course
  Journal of the Neurological Sciences, 2006